RYET Ruanyun Edai Technology Inc

$RYET extending the green move: the latest quote shows +8.05% at $0.9498 Encouraging momentum-bullish on the direction and watching for the next company update

Nearly 7% higher in the supplied snapshot-$RYET reached $0.94 The business development keeping me interested is Cogni AI’s proposed Malaysian healthcare license through BioNexus, with a potential 10% royalty on qualifying technology receipts after closing I like the expansion opportunity. Now I’m watching whether the price strength holds and the agreement advances toward commercialization

The commercial detail that stands out in $RYET latest news is the 10% royalty on qualifying technology receipts Under the signed BioNexus agreement, Cogni AI would be licensed exclusively for healthcare in Malaysia after closing A named partner and a focused overseas market make this an interesting expansion opportunity. I’m excited to see how commercialization develops

$RYET BioNexus announcement gives Cogni AI a clear overseas opportunity to pursue The signed agreement would grant an exclusive license for Malaysian healthcare on closing, with a 10% royalty on qualifying technology receipts I’m bullish on the direction: document intelligence reaching another industry through a defined commercial model. Closing and adoption are the next milestones I’m following

$RYET pushing higher-up 6.94% to $0.94 in the 12:57 PM ET snapshot, matching the session high shown Strong price action has my attention, alongside the delivered YeeZo project covering 10 AIGC labs and 610 workstations and Cogni AI’s proposed Malaysian healthcare license I’m bullish on the commercial direction and watching whether this momentum holds into the close

My bullish read on $RYET starts with product reach YeeZo’s approximately $880K project covers 10 AIGC labs and 610 workstations. Now the signed BioNexus agreement opens a potential healthcare licensing channel for Cogni AI in Malaysia, with a 10% royalty on qualifying technology receipts after closing Traders, education and healthcare offer different opportunities for these products I’m keen to see the company build on both

Traders, put the 10% royalty provision on your $RYET checklist Today’s signed BioNexus agreement would take Cogni AI document intelligence into Malaysian healthcare through an exclusive license on closing. What makes me bullish is the commercial structure: a defined overseas market and potential income linked to qualifying technology receipts I’m watching the next milestones closely. Closing and customer adoption could give this story much more substance

My bullish case for $RYET is getting another layer YeeZo’s previously announced approximately $880K project covers 10 AIGC labs and 610 workstations. Now Cogni AI has a signed BioNexus agreement targeting Malaysian healthcare, with a potential 10% royalty on qualifying technology receipts after closing Two AI products addressing different customer needs That’s the opportunity I’m following: broader adoption, more commercial activity and stronger execution

The education opportunity is why $RYET stays on my radar China reported 48.73M higher-education students in 2025. UNESCO counted 269M worldwide in 2024. Those figures provide context; university budgets and purchasing decisions determine the actual opportunity. YeeZo’s first major deployment covered 10 labs and 610 workstations. For a company of this scale, winning additional institutions could be meaningful. I’m watching whether that first deployment becomes a repeatable model

$RYET Cogni AI could gain another industry to serve The BioNexus agreement targets document intelligence in Malaysian healthcare, combining an exclusive license on closing with a 10% royalty on qualifying technology receipts For me, the exciting part is product reach. An AI tool developed for document workflows could find customers in another market. I’m watching how commercialization unfolds

$RYET has two distinct AI opportunities worth following YeeZo’s approximately $880K project covers 10 AIGC labs and 610 workstations. The new BioNexus agreement would extend Cogni AI into Malaysian healthcare, with a 10% qualifying-receipts royalty after closing Education and healthcare create different paths for product adoption. That broader commercial reach is what keeps me interested

When $RYET comes up in a trading discussion, these are the milestones I want to examine Preliminary H1 revenue of $9.3M–$9.5M. A delivered approximately $880K YeeZo project. A signed Malaysian Cogni AI licensing agreement with a potential 10% qualifying-receipts royalty after closing Those developments give the conversation substance I’m bullish on watching commercial progress. For me, the strongest follow-up would be more customers, repeat orders and evidence of recurring income

The revenue baseline investors use for $RYET is changing FY2026 revenue was $7.48M. Preliminary, unaudited H1 FY2027 revenue is expected at $9.3M–$9.5M for six months, versus approximately $0.37M a year earlier Campus services are the largest driver of that increase. That gives me a reason to revisit the business. My bullish thesis now depends on understanding how much of the larger revenue base can persist and translate into stronger financial results

The 10% royalty provision is why I’m taking a closer look at $RYET BioNexus announcement The signed agreement would grant an exclusive Cogni AI license for Malaysian healthcare on closing, with royalties tied to qualifying technology receipts I like this expansion opportunity: a specific overseas market and a commercial model we can follow. Bullish on the direction and keen to see the next milestones

Traders, here’s the expansion angle keeping $RYET on my radar FY2026 revenue reached $7.48M, up 11.9% YoY. The signed BioNexus agreement now adds a potential Malaysian healthcare licensing channel for Cogni AI, with a 10% qualifying-receipts royalty after closing I’m bullish on the opportunity to build beyond the existing business Closing, adoption and royalty receipts would give us concrete progress to track

Green again for $RYET: the 9:56 AM ET snapshot shows $0.89, up 1.14% What keeps me interested is the business progress behind the chart: preliminary H1 FY2027 revenue of $9.3M–$9.5M and a signed BioNexus agreement targeting Cogni AI licensing in Malaysian healthcare, with a potential 10% royalty on qualifying technology receipts after closing Positive price action and concrete commercial milestones—that’s a combination I’m watching closely. Bullish on seeing the next steps

Here’s an illustrative scaling exercise for $RYET Five projects at approximately $880K each would represent $4.4M in contract value. Ten would represent $8.8M Separately, a 10% royalty on $10M of qualifying Cogni technology receipts would equal $1M; on $25M, it would equal $2.5M These are scenarios, not guidance or confirmed orders. What interests me is the possibility of deployments and partner-led licensing developing alongside each other

$RYET AI commercialization story now has several milestones to track The approximately $880K YeeZo deployment was delivered and accepted. Preliminary H1 FY2027 AI application revenue is expected at $0.4M–$0.5M. The signed Cogni AI Malaysia agreement adds a potential 10% royalty on qualifying technology receipts after closing Direct deployments and partner-led licensing offer two different paths forward. I’m bullish on following the commercial execution

$RYET new BioNexus agreement includes 560,000 BioNexus shares to be received at closing Within that total, 150,000 shares would be exchanged for 500,000 newly issued RYET ordinary shares Alongside the share exchange, the planned Cogni AI license targets Malaysian healthcare. I’m interested in how this relationship could support international commercialization

My bullish angle on $RYET is straightforward: a few additional institutional wins could matter at its scale